Dry Eye Treatment Devices Market Trends Analysis Report 2023-2030 with Competitive Analysis of Sight Sciences, Lumenis, ESW Vision, Johnson & Johnson, Alcon, & MiBo Medical Group
24 oct. 2023 11h18 HE
|
Research and Markets
Dublin, Oct. 24, 2023 (GLOBE NEWSWIRE) -- The "Dry Eye Treatment Devices Market Size, Share & Trends Analysis Report By Technology (MGX, Combination (MGX+IPL)), By End-use (Hospitals, Ophthalmic...
OKYO Pharma Announces Positive Safety Data Profile for the ongoing OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease ("DED")
05 oct. 2023 07h00 HE
|
OKYO Pharma LTD
Over 95% of randomized DED patients have completed 4 weeks of dosing in the planned 12-week Phase 2 trial, with 72% of randomized DED patients completing 8 weeks, and 7.1% of patients completing the...
Growing Demand for Painless LASIK Surgeries Drives Opportunities in the Global Refractive Surgery Devices Market 2023-2030
28 sept. 2023 07h13 HE
|
Research and Markets
Dublin, Sept. 28, 2023 (GLOBE NEWSWIRE) -- The "Global Refractive Surgery Devices Market by Product Type (Aberrometers, Microkeratome, Ophthalmic Laser), Application (Astigmatism, Dry Eyes,...
OKYO Pharma Completes Enrollment in Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease
08 sept. 2023 07h00 HE
|
OKYO Pharma LTD
Full enrollment achieved on September 6th with a total of 240 patients enrolled in studyTop-line data planned for release in December 2023Phase 2 trial is designed as a potential registration trial,...
OKYO Pharma Achieves 90% Enrollment in 240-Patient Phase 2 Clinical Trial of OK-101 to treat Dry Eye Disease (“DED”)
30 août 2023 07h00 HE
|
OKYO Pharma LTD
Full enrollment anticipated by first week of SeptemberOKYO on schedule to release top-line data before end of 2023Phase 2 trial is designed as potential registration trial with pre-specified primary...
OKYO Pharma Announces Appointment of William A. Clementi as Chief Operating Officer
27 juil. 2023 11h30 HE
|
OKYO Pharma LTD
LONDON and NEW YORK, July 27, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye disease...
Dry Eye Disease Treatment Devices Global Industry Report 2023: Global Market Revenue to Reach over US$327 Mn in 2030
05 juil. 2023 10h33 HE
|
Fairfield Consultancy Services OPC Pvt Ltd
London, July 05, 2023 (GLOBE NEWSWIRE) -- Primarily driven by ageing, dry eye condition recently prevalent due to prolonged exposure to digital screens. Increasing demand for effective dry eye...
OKYO Pharma Announces Randomized Segment Now Underway in Phase 2 Clinical Trial of Topical Ocular OK-101 for Dry Eye Disease
06 juin 2023 09h30 HE
|
OKYO Pharma LTD
Trial designed with a two-week run-in period to reduce the well-known placebo effect in trials involving pain componentTop-line data from trial anticipated in Q4, 2023 LONDON and NEW YORK, June 06,...
Dry Eye Syndrome Market Size to Surpass USD 11.26 Billion in 2030, exhibiting a CAGR of 7.0%
24 mai 2023 09h27 HE
|
Fortune Business Insights
Pune, India, May 24, 2023 (GLOBE NEWSWIRE) -- According to Fortune Business Insights, global Dry Eye Syndrome Market size was valued at USD 6.61 billion in 2022 and is projected to grow from USD...
OKYO Pharma Now Participating on the Webull Corporate Communications Service Platform
11 mai 2023 07h00 HE
|
OKYO Pharma LTD
LONDON and NEW YORK, May 11, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat dry eye...